Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

RCT (n=1087) found KRd regimen did not improve progression-free survival vs. VRd regimen and had more toxicity, therefore VRd triplet regimen remains standard of care for induction therapy for patients with standard-risk and intermediate-risk newly diagnosed multiple myeloma.

SPS commentary:

In study, median progression-free survival was 34.6 months with KRd regimen comprising carfilzomib, a next-generation proteasome inhibitor, in combination with lenalidomide and dexamethasone, and 34.4 months in VRd (bortezomib, lenalidomide, and dexamethasone) group (hazard ratio 1.04, 95% CI 0.83–1.31; p=0.74); median overall survival has not been reached in either group.


The Lancet Oncology